GlassScriptPhysician profile
Jonathan M Rippentrop
NPI 1609874171
$14,556.82
in general payments reported to CMS, 2019-2025
29 companies · $2,318 in 2025
The $2,318 reported for 2025 was more than what 83% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,923 · 2020: $534 · 2021: $1,788 · 2022: $1,967 · 2023: $422 · 2024: $1,605 · 2025: $2,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280 · Travel and Lodging: $2,056 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.17 |
| Travel and Lodging | $2,055.59 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,272.71 | 2019-2025 | |
| Teleflex LLC | $2,746.32 | 2021-2024 | Urolift |
| Neotract INC. | $1,480.34 | 2019-2020 | |
| Procept Biorobotics Corporation | $842.46 | 2025 | |
| 180 Medical, INC. | $443.25 | 2019-2024 | Gentlecath, Cure Catheter, Gentlecath Glide |
| Janssen Biotech, INC. | $345.72 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $265.48 | 2020-2022 | |
| Pfizer INC. | $238.03 | 2019-2024 | |
| Dendreon Pharmaceuticals LLC | $100.78 | 2019-2024 | Provenge |
| Abbvie INC. | $100.69 | 2022-2025 | Botox |
| Boston Scientific Corporation | $99.39 | 2022-2024 | Advance Xp |
| Axonics, INC. | $83.40 | 2021-2023 | Bulkamid, Axonics |
| Merck Sharp & Dohme LLC | $75.43 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $64.66 | 2019-2023 | |
| Verity Pharmaceuticals INC. | $55.77 | 2022-2023 | Trelstar |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $42.96 | 2021-2023 | Edex, Xiaflex, Aveed |
| Urogen Pharma, INC. | $42.59 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $36.70 | 2025 | Aptra |
| Blue Earth Diagnostics | $35.00 | 2019 | |
| Coloplast Corp | $33.23 | 2020-2021 | |
| Cook Medical LLC | $29.04 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $21.34 | 2023 | Pylarify |
| Amgen INC. | $20.07 | 2019 | |
| Endo USA, INC. | $15.37 | 2025 | Xiaflex |
| Telix Pharmaceuticals | $13.96 | 2023 | Illuccix |
| Vertex Pharmaceuticals Incorporated | $13.52 | 2025 | |
| Myovant Sciences INC. | $13.38 | 2021 | |
| Olympus America INC. | $13.10 | 2023 | Itind System |
| Palette Life Sciences, INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rippentrop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.